Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.94 USD | +1.71% | +12.03% | +57.31% |
Apr. 15 | CorMedix's DefenCath Now Commercially Available For US Inpatient Use | MT |
Apr. 15 | CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin) | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.31% | 321M | |
+12.55% | 9.3B | |
-13.75% | 5.01B | |
+41.51% | 4.47B | |
+4.51% | 3.96B | |
+21.10% | 2.44B | |
-15.23% | 2.41B | |
-25.12% | 2.23B | |
+19.51% | 2.02B | |
+5.93% | 1.69B |
- Stock Market
- Equities
- CRMD Stock
- News CorMedix Inc.
- CorMedix : B. Riley Adjusts CorMedix' Price Target to $25 From $11, Keeps Buy Rating